Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04076215
Other study ID # 6263-19-SMC
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 2019
Est. completion date June 2020

Study information

Verified date August 2019
Source The Chaim Sheba Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-traumatic stress disorder (PTSD) is characterized by physiological changes, some of which are thought to be chronic, while others are observed in response to stressogenic stimuli. A psychiatric diagnosis of PTSD is currently based mainly on non-quantitative elements, such as interviews and subjective impressions. Discernable patterns of stress-related measures may constitute a physiological and biochemical phenotype characteristic of PTSD, which may serve as a biomarker and support diagnostic decisions, as well as personalized treatment plans.

The current study is aimed at examining the possibility of basing a psychiatric diagnosis by measuring changes in the biochemical phenotype of participants with PTSD. Physiological and biochemical data will be collected from participants with and without PTSD using wearable sensors and adhesive biosensor patches. The data will be collected in two conditions: in a neutral, quiet situation, and during and following exposure to controlled stressogenic stimuli.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date June 2020
Est. primary completion date February 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria:

- PTSD diagnosis (excluding controls)

- Proper ability to give informed consent

Exclusion Criteria:

- Active oncological/cardiovascular condition

- Dialysis patients

- Active psychotic or suicidal symptoms

- Severe dissociative symptoms

- A traumatic brain injury (TBI) diagnosis

- Pregnancy

Study Design


Intervention

Behavioral:
Stressogenic stimulus
Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting
Device:
Biobeat smart watch and adhesive biosensor patches.
Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Nadav Goldental

Outcome

Type Measure Description Time frame Safety issue
Primary Significant differences between groups - HRV Significant differences in Heart Rate Variability - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in physiological changes between groups - temperature Significant differences in physiological changes - body temperature- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in physiological changes between groups - SPO2 Significant differences in physiological changes - Saturation SPO2- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in physiological changes between groups - blood pressure Significant differences in physiological changes - continuous blood pressure- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in physiological changes between groups - pulse pressure Significant differences in physiological changes - pulse pressure - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in physiological changes between groups -respiratory rate Significant differences in physiological changes - respiratory rate- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in physiological changes between groups -stroke volume Significant differences in physiological changes - stroke volume- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in physiological changes between groups -cardiac output Significant differences in physiological changes - cardiac output - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in physiological changes between groups - systemic vascular resistance Significant differences in physiological changes - systemic vascular resistance- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in cortisol levels between groups Significant differences in biochemical changes - cortisol - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - C-reactive protein Significant differences in biochemical changes - C-reactive protein - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - Interleukin 6 Significant differences in biochemical changes - Interleukin 6 - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - N-terminal B-type natriuretic peptide Significant differences in biochemical changes - N-terminal B-type natriuretic peptide - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - 8-oxo-7 Significant differences in biochemical changes - 8-oxo-7- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - 8-dihydro-2'-deoxyguanosine Significant differences in biochemical changes - 8-dihydro-2'-deoxyguanosine - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - hexanone Significant differences in biochemical changes - hexanone - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - acetic acid Significant differences in biochemical changes - acetic acid - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - heptane Significant differences in biochemical changes - heptane - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - hexanal Significant differences in biochemical changes -hexanal - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - 3-heptanone Significant differences in biochemical changes - 3-heptanone - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - hexanoic acid Significant differences in biochemical changes - hexanoic acid - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - heptanal Significant differences in biochemical changes -heptanal - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - nonanal Significant differences in biochemical changes - nonanal - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
Primary Significant differences in biochemical changes between groups - glucose Significant differences in biochemical changes - glucose - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli 3 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Recruiting NCT05934175 - Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder N/A
Recruiting NCT05934162 - Efficacy of Internet-delivered Cognitive-behavior Therapy for PTSD N/A
Completed NCT04460014 - Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT N/A
Recruiting NCT05877807 - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Active, not recruiting NCT05992649 - The Effect of Aquatic Physiotherapy on Veterans Suffering From PTSD - a 40-week Pilotproject N/A
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Not yet recruiting NCT05331534 - Effect of Attentional Therapy on Post-traumatic Stress Disorder N/A
Not yet recruiting NCT03649607 - Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black N/A
Not yet recruiting NCT02545192 - A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments Phase 1
Completed NCT02329418 - Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit N/A
Active, not recruiting NCT00978484 - A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder Phase 3
Completed NCT00760734 - Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD) Phase 1
Completed NCT03278171 - Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
Recruiting NCT05874362 - People Bereaved by Violent Death : Negative Event Biases and Temporal Perception N/A
Terminated NCT03898843 - Assisted Animal Therapy: ReAnimal N/A
Recruiting NCT04747379 - Psychological Effect of Explicit Recall After Sedation (PEERS)
Completed NCT03248167 - Cannabidiol as a Treatment for AUD Comorbid With PTSD Phase 1/Phase 2
Recruiting NCT03503981 - Examining Change Mechanisms in Psychotherapy